Skip to main content

This job has expired

You will need to login before you can apply for a job.

Senior Research Associate, AAV Process Development

Employer
Intellia Therapeutics
Location
Cambridge, MA, United States
Start date
Jan 29, 2021

View more

Discipline
Engineering, Manufacturing & Production, Process, Science/R&D, Research
Required Education
Bachelors Degree
Position Type
Full time
Hotbed
Genetown

Job Details

Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We want all of our people to go beyond what is possible. We aren't constrained by typical end rails, and we aren't out to just treat people. We're all in this for something more. We're driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

Intellia is seeking a skilled and motivated Senior Research Associate to support AAV process development in the Technical Operations group. The ideal applicant will be experienced and capable in upstream or downstream processes for AAV production. Experience with bioreactor suspension culture and scalable downstream processes under GMP is a plus. Team work, versatility, and strong problem solving skills are required.

RESPONSIBILITIES:
  • AAV upstream or downstream process development for various unit operations including cell culture, transfection, harvest and clarification, affinity and ion-exchange chromatography, and tangential flow filtration.
  • Develop and perform pre-clinical scale up production processes based on QbD.
  • Perform analytical assays to support process development and production runs.
  • Collaborative integration within Tech Ops and with R&D and Automation groups.
  • Develop SOPs and assist in technology transfers to strategic partners and CMOs.
  • Provide high quality data and ELN documentation to drive decision making in the CMC team.
  • Operate and maintain multiple laboratory instruments.


QUALIFICATIONS:
  • Bachelor's degree in Biology, Virology, Chemical Engineering or related area with 2-4 years of hands on industrial experience, or master's degree with 0-2 years of industry experience.
  • Experience with suspension AAV production or purification is required.
  • Proficiency with relevant cell culture and aseptic technique or filtration- or chromatography-based purification methods is required.
  • Experience in virus production in bench-scale and pilot-scale bioreactors or under a GMP environment is a plus.
  • Experience with analytical assays including ddPCR/qPCR, ELISA, HPLC, DLS or CE-SDS is a plus.
  • Organized, detail-oriented, and a self-starter who continuously seeks innovative solutions.
  • Excellent verbal and written communication skills.


EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert